ARRY-614, p38/Tie2 inhibitor; oral

DRUG2 trials

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer

Conditions

Myelodysplastic Syndromes

Phase 1

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

CompletedNCT00916227

Array Biopharma, now a wholly owned subsidiary of PfizerMyelodysplastic Syndromes

Start: 2009-06-30Updated: 2020-09-09

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

CompletedNCT01496495

Array Biopharma, now a wholly owned subsidiary of PfizerMyelodysplastic Syndromes

Start: 2012-01-31End: 2015-03-18Updated: 2020-09-09